CT-868 clinical trials
Also written CT-868.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses CT-868 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses CT-868 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of CT-868 in Type 1 Diabetes MellitusCompletedPhase 2Carmot Therapeutics, Inc.NCT06062069Written as CT-868
- A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedPhase 2Carmot Therapeutics, Inc.NCT05110846Written as CT-868
- A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood GlucoseCompletedPhase 1Carmot Therapeutics, Inc.NCT04973111Written as CT-868 as SC Injection
- A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesCompletedPhase 1Carmot Therapeutics, Inc.NCT05794581Written as CT-868
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- A Study of CT-868 in Type 1 Diabetes MellitusOct 28, 2026NCT06062069